BiotechTube

XL092 + Atezolizumab + Regorafenib

Phase 3Active
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Colorectal Cancer

Conditions

Colorectal Cancer

Trial Timeline

Sep 7, 2022 → Jan 1, 2027

NCT ID
NCT05425940

About XL092 + Atezolizumab + Regorafenib

XL092 + Atezolizumab + Regorafenib is a phase 3 stage product being developed by Exelixis for Colorectal Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05425940. Target conditions include Colorectal Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05425940Phase 3Active

Competing Products

20 competing products in Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
52
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
52
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
ALIMTA + OxaliplatinEli LillyPhase 2
52
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
Bevacizumab + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 1/2
41
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOXChugai PharmaceuticalPhase 2/3
65
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
CPT-11 and TS-1 + CPT-11, 5-FU and l-LVDaiichi SankyoPhase 2/3
65
CPT-11 based regimensDaiichi SankyoPre-clinical
23
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)Daiichi SankyoPhase 2
52
Tivantinib + Placebo + Cetuximab + IrinotecanDaiichi SankyoPhase 1/2
41
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3WDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
CS-1008 + irinotecanDaiichi SankyoPhase 2
52
CS-7017 + PlaceboDaiichi SankyoPhase 2
52
Patritumab DeruxtecanDaiichi SankyoPhase 2
52
CS-1008 + FOLFIRIDaiichi SankyoPhase 1
33
DS-8273a + nivolumabDaiichi SankyoPhase 1
33

Other Products from Exelixis

Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsuleApproved
82
cabozantinib + prednisonePhase 3
74
Cabozantinib tablets + Everolimus (Afinitor) tabletsPhase 3
74
XL184 + PlaceboPhase 3
74
cabozantinib + mitoxantrone + prednisonePhase 3
74